ClinicalTrials.gg
Not yet recruitingNCT07937566Updated Nov 16, 2026

Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

An observational study in Mantle Cell Lymphoma, sponsored by Fondazione Italiana Linfomi - ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Fondazione Italiana Linfomi - ETS · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS — 3 open to participants now, 5 under way, none of them phase 3. Lymphoma, Mantle-Cell · Fondazione Italiana Linfomi - ETS.

Started
2027
the only one that year
Observational
3 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS, this one is the only one that started in 2027, is one of 3 observational ones, and was the 12th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

3 of the 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS, or all of them as a file.
02

Study summary

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.

In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.

Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.

We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • Bruton's tyrosine kinase inhibitors
  • BTKi
  • ibrutinib
  • acalabrutinib
  • zanubrutinib
  • pirtobrutinib
  • regimen
  • treatment-Naïve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria:

  • confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
  • Age ≥ 18 years at the time of BTKi-based treatment initiation.
  • Patients who are able to understand the nature and objectives of the study and who have provided written , approved by the Independent Ethics Committee (IEC), for participation in the observational study.

For the retrospective enrollment group:

In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:

● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.

For the prospective enrollment group:

In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:

● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.

Exclusion criteria

Exclusion criteria:

  • Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
  • Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
  • Inability or unwillingness to provide written , where required by applicable ethical and regulatory requirements.
  • Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective enrollment group

    Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.

  • Prospective enrollment group

    Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.

06

What researchers measure

Primary outcomes

  1. Best overall response

    Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  2. Progression-free survival (PFS)

    Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  3. Overall survival (OS)

    Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  4. Event-free survival (EFS)

    Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  5. Time to next treatment (TTNT)

    Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  6. Duration of response (DOR)

    Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  7. Non-relapse mortality (NRM)

    Defined as death without prior relapse or progression

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  8. POD24

    Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  9. Incidence of adverse events

    Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  10. Incidence of deaths

    Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Secondary outcomes

  1. Treatment duration

    Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  2. Treatment discontinuation

    Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

  3. Treatment modifications

    Frequency and reasons for dose reductions, interruptions and other modifications.

    Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Mar 2042, 180 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Mar 2027
Primary completionEst.
Mar 2042
CompletionEst.
Mar 2042
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937566
Lead sponsor
Fondazione Italiana Linfomi - ETS
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Mar 2027 (estimated)
Primary completion
Mar 2042 (estimated)
Completion
Mar 2042 (estimated)
Last update
Nov 16, 2026

Study contacts

Uffici Studi FIL
Contact
startup@filinf.it
+390131033153
Uffici Studi FIL
Contact
gestionestudi@filinf.it
+390599769913
Marco Ladetto, MD
principal investigator · S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion